AstraZeneca (NYSE:AZN) Shares Gap Up - Here's What Happened

Key Points

• AstraZeneca shares jumped 7.1%, opening at $183.59 after closing at $174.40, following better-than-expected third-quarter results.
• Core EPS reached $2.79 versus the $2.60 consensus, while revenue rose 6.5% year over year to $16.21 billion. Oncology sales increased 17%, driving growth despite generic pressure on mature medicines such as Farxiga.
• Management reaffirmed its 2026 growth outlook and announced a goal of $1.5 billion in annual savings, while reporting 12 positive Phase 3 readouts. Analysts maintain a generally favorable view, with a “Moderate Buy” consensus and a $206.67 price target, although generic competition and liquidity concerns remain.

AstraZeneca Plc (NYSE:AZN - Get Free Report)'s stock price gapped up before the market opened on Friday. The stock had previously closed at $174.40, but opened at $183.59. AstraZeneca shares last traded at $185.9280, with a volume of 935,803 shares.

Key Stories Impacting AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Core EPS was $2.79 versus consensus estimates near $2.59–$2.60, while revenue reached approximately $16.2 billion, ahead of the roughly $16.0 billion forecast and up about 7% year over year. Net profit rose to $3.12 billion from $2.535 billion. AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth
• Positive Sentiment: Oncology sales were the primary growth engine. Cancer-drug revenue increased 17%, helping offset generic pressure on mature medicines, including the impact from Farxiga competition. The performance reinforces AstraZeneca’s strategy of shifting its portfolio toward innovative, higher-growth therapies. AstraZeneca Q3 profit beats estimates as cancer drug sales drive growth
• Positive Sentiment: Management reaffirmed fiscal 2026 guidance. The company continues to target mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. AstraZeneca also outlined a goal of $1.5 billion in annual savings, which could support margins and earnings. AstraZeneca targets $1.5 billion in annual savings
• Positive Sentiment: Pipeline progress added to the favorable reaction. AstraZeneca reported 12 positive Phase 3 readouts, improving confidence in future product launches and the company’s ability to replenish revenue as older drugs face patent and generic pressures. AstraZeneca Q3 Profit Rises; Pipeline Delivers 12 Positive Phase 3 Readouts
• Neutral Sentiment: Analyst views remained mixed: Guggenheim maintained a Buy rating, while Deutsche Bank kept a Hold rating. Erste Group Bank reportedly lowered its fiscal 2026 EPS estimate, indicating that some concerns about execution, competition and the drug portfolio remain.
• Negative Sentiment: Generic erosion on mature medicines remains a headwind, particularly as Farxiga faces increased competition. The company’s current ratio and quick ratio below 1 also underscore relatively limited short-term balance-sheet liquidity, although the earnings release was the dominant market catalyst.

Analyst Ratings Changes

AZN has been the topic of a number of research reports. Citigroup restated a "buy" rating on shares of AstraZeneca in a research note on Tuesday, October 6th. Royal Bank Of Canada began coverage on AstraZeneca in a report on Tuesday, September 8th. They set an "outperform" rating for the company. Wall Street Zen downgraded AstraZeneca from a "buy" rating to a "hold" rating in a research report on Sunday, October 11th. HSBC lowered shares of AstraZeneca from a "buy" rating to a "hold" rating in a research note on Monday, July 13th. Finally, Weiss Ratings raised shares of AstraZeneca from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Monday. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $206.67.

AstraZeneca Stock Up 7.1%

The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89. The company has a market cap of $289.72 billion, a price-to-earnings ratio of 27.91, a price-to-earnings-growth ratio of 1.31 and a beta of 0.27. The business has a 50-day simple moving average of $164.05 and a 200-day simple moving average of $180.22.

AstraZeneca (NYSE:AZN - Get Free Report) last announced its quarterly earnings data on Saturday, October 31st. The company reported $2.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.60 by $0.19. AstraZeneca had a return on equity of 31.45% and a net margin of 17.02%. The business had revenue of $16.21 billion during the quarter, compared to analysts' expectations of $16 billion. During the same quarter last year, the business posted $2.38 EPS. The business's quarterly revenue was up 6.5% compared to the same quarter last year. On average, equities analysts anticipate that AstraZeneca Plc will post 10.21 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AZN. Amundi grew its position in shares of AstraZeneca by 146,574.4% during the first quarter. Amundi now owns 15,386,149 shares of the company's stock worth $3,034,456,000 after acquiring an additional 15,375,659 shares during the last quarter. Janus Henderson Group PLC raised its position in AstraZeneca by 889.9% in the 1st quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company's stock valued at $2,319,947,000 after purchasing an additional 10,742,268 shares during the last quarter. Rathbones Group PLC boosted its stake in AstraZeneca by 106,772.0% during the 1st quarter. Rathbones Group PLC now owns 8,054,943 shares of the company's stock worth $1,560,419,000 after purchasing an additional 8,047,406 shares during the period. Royal Bank of Canada boosted its stake in AstraZeneca by 208.6% during the 1st quarter. Royal Bank of Canada now owns 10,386,455 shares of the company's stock worth $2,048,417,000 after purchasing an additional 7,021,126 shares during the period. Finally, Swiss National Bank purchased a new position in AstraZeneca during the 1st quarter worth $1,202,714,000. Institutional investors and hedge funds own 20.35% of the company's stock.

About AstraZeneca

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.